Publications by authors named "Nikoleta A Xixi"
Article Synopsis
- Immunomodulators, which are used to treat COVID-19, do not appear to improve outcomes for immunocompromised patients without increasing risks of secondary infections.
- A review of eleven randomized controlled trials with 397 patients showed no significant differences in mortality or infection rates between those treated with immunomodulators and those receiving standard care.
- The findings suggest that immunomodulators provide no clear benefit or harm for immunocompromised patients hospitalized due to COVID-19, according to the study conducted.
Background: We attempted to investigate the change in mortality of intubated patients with coronavirus disease (COVID-19) from first to subsequent waves across several countries.
Methods: We pre-registered our meta-analysis with PROSPERO [Anonymized]. We searched PubMed, Scopus, and gray literature for observational studies reporting data on all-cause mortality of intubated patients with COVID-19 recruited both during first and subsequent waves of the pandemic.
Purpose: Optimal timing of intubation is controversial. We attempted to investigate the association between timing of intubation and clinical outcomes of critically ill patients.
Methods: PubMed was systematically searched for studies reporting on mortality of critically ill patients undergoing early versus late intubation.
Background: Whether vitamin C provides any benefit when administered in critically ill patients, including those with coronavirus disease (COVID-19), is controversial. We endeavored to estimate the effect of administration of vitamin C on clinical outcomes of critically ill patients with COVID-19 by performing an observational study and subsequent meta-analysis.
Methods: Firstly, we conducted an observational study of critically ill patients with laboratory-confirmed COVID-19 who consecutively underwent invasive mechanical ventilation in an academic intensive care unit (ICU) during the second pandemic wave.